• +1-646-491-9876
    • +91-20-67278686

    Search

    Protein Kinase C Theta Type-Pipeline Review H1 2017

    Protein Kinase C Theta Type-Pipeline Review H1 2017

    • Report Code ID: RW0001834358
    • Category Pharmaceuticals
    • No. of Pages 31
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Pipeline Review, H1 2017

    Summary

    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Protein Kinase C Theta Type - Pipeline Review, H1 2017, outlays comprehensive information on the Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Protein kinase C theta (PKC-θ) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor (TCR) signaling, including T-cells activation, proliferation, differentiation and survival, by mediating activation of multiple transcription factors such as NF-kappa-B, JUN, NFATC1 and NFATC2. In TCR-CD3/CD28-co-stimulated T-cells, is required for the activation of NF-kappa-B and JUN. It plays an indirect role in activation of the non-canonical NF-kappa-B (NFKB2) pathway. It mediate inhibitory effects of free fatty acids on insulin signaling by phosphorylating IRS1 which in turn blocks IRS1 tyrosine phosphorylation and downstream activation of the PI3K/AKT pathway. The molecules developed by companies in Preclinical and Discovery stages are 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Infectious Disease, Oncology, Metabolic Disorders and Undisclosed which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS) , Autoimmune Disorders, Ewing Sarcoma, Heart Transplant Rejection, Inflammation, Insulin Resistance, Kidney Cancer (Renal Cell Cancer) , Kidney Transplant Rejection, Obesity, Prostate Cancer, Rheumatoid Arthritis, Type 2 Diabetes and Unspecified.

    Furthermore, this report also reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
    - The report reviews Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Overview
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Molecule Type
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Companies Involved in Therapeutics Development
    AbbVie Inc
    Astellas Pharma Inc
    Celgene Corp
    CompleGen Inc
    Takeda Pharmaceutical Company Ltd
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Drug Profiles
    AS-2521780 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CC-0739623 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CGX-0471 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CGX-1079 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    englerin A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit PKC-Theta - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Ewing Sarcoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Protein Kinase C Theta for Autoimmune Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Dormant Products
    Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 2.7.11.13) - Discontinued Products
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by AbbVie Inc, H1 2017
    Pipeline by Astellas Pharma Inc, H1 2017
    Pipeline by Celgene Corp, H1 2017
    Pipeline by CompleGen Inc, H1 2017
    Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    AbbVie Inc
    Astellas Pharma Inc
    Celgene Corp
    CompleGen Inc
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//protein-kinase-c-theta-type-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//protein-kinase-c-theta-type-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//protein-kinase-c-theta-type-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments